Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares traded 6.02% higher at $11.28 on Wall Street last session.
In accordance with the data, 8 analysts cover Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $12.00, we find $14.00. Given the previous closing price of $10.64, this indicates a potential upside of 31.58 percent. AUPH stock price is now 6.92% away from the 50-day moving average and 41.26% away from the 200-day moving average. The market capitalization of the company currently stands at $1.63B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
It has been rated a hold by 2 analysts and a buy by 5. Brokers who have rated the stock have averaged $13.71 as their price target over the next twelve months.
.
In other news, MILNE GEORGE M JR, Director bought 20,000 shares of the company’s stock on Mar 02. The stock was bought for $178,284 at an average price of $8.91. Upon completion of the transaction, the Director now directly owns 70,000 shares in the company, valued at $0.79 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 02, Chief Executive Officer Greenleaf Peter sold 32,750 shares of the business’s stock. A total of $292,785 was realized by selling the stock at an average price of $8.94. This leaves the insider owning 982,968 shares of the company worth $11.09 million. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AUPH stock. A new stake in Aurinia Pharmaceuticals Inc. shares was purchased by JEFFERIES FINANCIAL GROUP INC. during the first quarter worth $2,256,000. EAM INVESTORS, LLC invested $1,764,000 in shares of AUPH during the first quarter. In the first quarter, WALLEYE TRADING LLC acquired a new stake in Aurinia Pharmaceuticals Inc. valued at approximately $1,456,000. NORGES BANK acquired a new stake in AUPH for approximately $1,286,000. GOTHAM ASSET MANAGEMENT, LLC purchased a new stake in AUPH valued at around $1,070,000 in the second quarter. In total, there are 254 active investors with 40.50% ownership of the company’s stock.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) opened at $10.67 on Monday. During the past 12 months, Aurinia Pharmaceuticals Inc. has had a low of $4.07 and a high of $13.41. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 10.10, and a quick ratio of 9.30. The fifty day moving average price for AUPH is $10.60 and a two-hundred day moving average price translates $8.00 for the stock.
The latest earnings results from Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.18, beating analysts’ expectations of -$0.22 by 0.04. This compares to -$0.27 EPS in the same period last year. The net profit margin was -65.90% and return on equity was -23.60% for AUPH. The company reported revenue of $34.41 million for the quarter, compared to $21.62 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 59.12 percent. For the current quarter, analysts expect AUPH to generate $38.15M in revenue.
Aurinia Pharmaceuticals Inc.(AUPH) Company Profile
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
